Hoth Therapeutics Signs a License Agreement with UMB and Isoprene Pharmaceuticals

 Hoth Therapeutics Signs a License Agreement with UMB and Isoprene Pharmaceuticals

Hoth Therapeutics Signs a License Agreement with UMB and Isoprene Pharmaceuticals

Shots: 

  • Hoth Therapeutics to get exclusive rights to evaluate UMB’s retinamides (RAMBAs) with an option to license the product to develop & commercialize therapies in the fields of dermatology and oncology 
  • The focus of the agreement is to develop UMB’s novel retinamide Retinoic acid metabolism blocking agents (RAMBAs) therapies for cancer and dermatological diseases
  • UMB’s RAMBAs are anticancer agents works against ATRA in cells providing therapeutic benefits to dermatological diseases including acne, eczema, psoriasis, cold sores, wounds, burns, sunburn, ichthyosis, skin cancer, and Kaposi’s Sarcoma

Click here to read full press release/ article | Ref: Hoth Therapeutics | Image: Plexuss

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post